Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Michael Untch"'
Autor:
Frederik Marmé, Helmut Forstbauer, Jens Huober, Gbg, Bruno Valentin Sinn, Michael Untch, Jenny Furlanetto, Christian Jackisch, Jens-Uwe Blohmer, Hans-Joachim Lück, Knut Engels, Ago-B, Grischa Wachsmann, Ekkehart Ladda, Nicole Burchardi, Elmar Stickeler, Sabine Schmatloch, Sibylle Loibl, Mattea Reinisch, Theresa Link, Volker Möbus, Carsten Denkert, Eva-Maria Grischke, Peter Klare, Marcus Schmidt, Christine Solbach, Andreas Schneeweiss, Julia Rey, Wolfgang Janni
Publikováno v:
European Journal of Cancer. 156:138-148
Background The GAIN-2 trial was designed to identify a superior intense dose-dense (idd) strategy for high-risk patients with early breast cancer. Here, we report an interim analysis, at which the predefined futility boundary was crossed. Patients an
Autor:
Guilherme Nader-Marta, Véronique Debien, Daniel Eiger, Zoi Tsourti, Rafael Caparica, Marie Kassapian, Sylvia Napoleone, Susanne Hultsch, Larissa Korde, Yingbo Wang, Saranya Chumsri, Kathleen I. Pritchard, Michael Untch, Meritxell Bellet-Ezquerra, Daniela Dornelles Rosa, Alvaro Moreno-Aspitia, Martine Piccart, Urania Dafni, Evandro de Azambuja
Publikováno v:
British journal of cancer. 127(10)
Patients with small node-negative HER2-positive breast cancer are commonly treated with paclitaxel and 1 year of adjuvant trastuzumab. We performed a sub-analysis of the ALTTO trial to explore the long-term outcomes of patients with small node-negati
Autor:
Scott D. Ramsey, Javier Cortes, Jipan Xie, Muhan Yuan, Michael Untch, Min Huang, Peter A. Fasching, Andrew Briggs, Gursel Aktan, Joyce O'Shaughnessy, John R. Cook, Jing Zhao, Chenyang Gu, Peter Schmid, Cynthia Z. Qi, Vassiliki Karantza, Amin Haiderali
Publikováno v:
Journal of the National Comprehensive Cancer Network. 18:1096-1104
Background: Pathologic complete response (pCR) is a common efficacy endpoint in neoadjuvant therapy trials for triple-negative breast cancer (TNBC). Previous studies have shown that pCR is strongly associated with improved long-term survival outcomes
Autor:
Frederik Marmé, Hans-Joachim Lück, Ralph Wirtz, Isabell Witzel, Carsten Denkert, Michael Untch, Karsten Weber, Christian Schem, Jens Huober, Peter A. Fasching, Volkmar Müller, Thomas Karn, Marion von Mackelenbergh, Sibylle Loibl, Elmar Stickeler
Publikováno v:
British Journal of Cancer
British journal of cancer : BJC 121(12), 1009-1015 (2019). doi:10.1038/s41416-019-0630-3
British journal of cancer : BJC 121(12), 1009-1015 (2019). doi:10.1038/s41416-019-0630-3
British journal of cancer : BJC 121(12), 1009-1015 (2019). doi:10.1038/s41416-019-0630-3
Published by Nature Publ. Group, Edinburgh
Published by Nature Publ. Group, Edinburgh
Autor:
Marion T. van Mackelenbergh, Fenja Seither, Volker Möbus, Joyce O'Shaughnessy, Miguel Martin, Heikki Joensuu, Michael Untch, Ulrike Nitz, Guenther G. Steger, Juan J. Miralles, Carlos H. Barrios, Masakazu Toi, Harry D. Bear, Hyman Muss, Toralf Reimer, Valentina Nekljudova, Sibylle Loibl
Publikováno v:
European journal of cancer (Oxford, England : 1990). 166
Despite the large number of patients with early breast cancer (EBC) who have been treated with capecitabine in randomised trials, no individual patient data meta-analysis has been conducted. The primary objective was to examine the effect of capecita
Autor:
Christian Schem, Julia Reid, A-R Hartman, Kirsten Timms, Christoph Salat, Peter A. Fasching, C. Jackisch, D. M. Zahm, Kerstin Rhiem, Carsten Denkert, Rita K. Schmutzler, Valentina Nekljudova, EP Elkin, Sherko Kümmel, B. Lederer, Mahdi Rezai, Bernd Gerber, Andreas Schneeweiss, S. Loibl, S. Penn, Karsten Weber, G. von Minckwitz, Michael Untch, Stefan Paepke, Eric Hahnen, Sascha D. Braun, J-U Blohmer, Peter Klare
Publikováno v:
Annals of Oncology. 29:2341-2347
Background In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival da
Autor:
Marion van Mackelenbergh, Peter A. Fasching, Andreas Schneeweiss, Michael Untch, Elmar Stickeler, Valentina Nekljudova, Frederik Marmé, Sabine Seiler, Jenny Furlanetto, Eva-Maria Grischke, Christian Schem, Carsten Denkert, Volkmar Müller, M Bassy, Thomas Karn, Sabine Schmatloch, Sibylle Loibl, C. Thode, D. Strik
Publikováno v:
European journal of cancer (Oxford, England : 1990). 152
Young women receiving chemotherapy for early breast cancer (EBC) have a high probability for ovarian failure, defined by chemotherapy-induced amenorrhea (CIA) as a surrogate. CIA is insufficiently reliable and reproducible. We analysed chemotherapy-i
Autor:
Claus Hanusch, Wolfgang D. Schmitt, Arndt Hartmann, Jenny Furlanetto, Andreas Schneeweiss, Peter A. Fasching, Karsten Weber, Gunter von Minckwitz, Berit M. Pfitzner, Aurelia Noske, Christian Schem, Jens Huober, Carsten Denkert, Barbara Ingold Heppner, Marion van Mackelenbergh, Christian Jackisch, Thomas Karn, Knut Engels, Peter Sinn, Bianca Lederer, Jens-Uwe Blohmer, Frederick Klauschen, Sherko Kümmel, Jan Budczies, Silvia Darb-Esfahani, Michael Untch, Sibylle Loibl
Publikováno v:
The Lancet Oncology. 19:40-50
Summary Background Tumour-infiltrating lymphocytes (TILs) are predictive for response to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, but their role in luminal breast cancer and the effect of TILs
Autor:
C. Thomssen, Jens Huober, Michael Untch, Gottfried E. Konecny, U. Nitz, H.-J. Lück, A. du Bois, Ingo B. Runnebaum, Christian M. Kurbacher, Volker Möbus, Walther Kuhn, C. Jackisch, Axel Hinke, G. von Minckwitz, Andreas Schneeweiss, Nadia Harbeck
Publikováno v:
Annals of Oncology. 29:178-185
Background Primary breast cancer (BC) patients with extensive axillary lymph-node involvement have a limited prognosis. The Arbeitsgemeinschaft fuer Gynaekologische Onkologie (AGO) trial compared intense dose-dense (idd) adjuvant chemotherapy with co
Autor:
Michael Untch, Peter A. Fasching, Miltiades Stephanou, Leyla Akpolat-Basci, Cornelia Liedtke, Max Bulsara, Hans-Christian Kolberg, Jayant S. Vaidya, Gyoergy Loevey
Publikováno v:
Reviews on Recent Clinical Trials. 12:93-100
Introduction: Targeted intraoperative radiotherapy (TARGIT - IORT) as a tumour bed boost after breast conserving surgery is well established for women with early breast cancer. A previous study from our group shows a beneficial effect of TARGIT-IORT